We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MICC:EURONEXT AMSTERDAMMagnum Ice Cream Co. N.V. Analysis

Data as of 2026-03-14 - not real-time

$15.50

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading below its short‑, medium‑ and long‑term moving averages, with a mid‑forties RSI and a bearish MACD histogram, indicating limited near‑term upside. Volume is on a downtrend and 30‑day volatility is elevated, while the beta is slightly above market, suggesting higher price swings. Valuation metrics such as the price‑to‑earnings ratio sit in the high‑twenties and price‑to‑book is markedly elevated, pointing to an overvalued stance relative to fundamentals, especially given a substantial debt load that dwarfs cash reserves. However, forward earnings estimates compress the PE to a more attractive level, and recent material developments – a new non‑executive director, inclusion in the AEX index, and the post‑spin‑off rally – provide a growth narrative that could support a medium‑term rebound.
Overall, the defensive consumer sector offers stability, but the combination of high leverage, lofty valuation multiples, and pronounced volatility tempers enthusiasm. Investors should weigh the short‑term technical weakness against the longer‑term upside potential tied to earnings improvements and index exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below key moving averages and bearish MACD
  • Decreasing volume and high short‑term volatility
  • Overvalued multiples relative to current earnings

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings compression reducing the PE
  • Inclusion in the AEX index enhancing visibility
  • Post‑spin‑off momentum and new board appointment

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong brand in a defensive consumer segment
  • High debt burden limiting financial flexibility
  • Potential for margin improvement if leverage is reduced

Key Metrics & Analysis

Financial Health

Revenue Growth-4.10%
Profit Margin3.70%
P/E Ratio28.2
ROE17.88%
ROA5.58%
Debt/Equity539.65
P/B Ratio13.1
Op. Cash Flow$483.0M
Free Cash Flow$204.0M

Technical Analysis

TrendNeutral
RSI44.1
Support$14.89
Resistance$17.01
MA 20$15.78
MA 50$16.49
MA 200$16.29
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Target Price$18.33
Upside/Downside18.28%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.09
Volatility69.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.